701906-29-8

Upstream product

• 140-10-3 (E)-3-phenylacrylic acid 
• 950773-38-3 R-(-)-[3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl]diisopropylamine 
• 124-38-9 carbon dioxide 
• 106-41-2 4-bromo-phenol 
• 156755-23-6 6-bromo-4-phenyl-3,4-dihydro-2H-chromen-2-one 
• 156755-24-7 methyl 3-[2-(benzyloxy)-5-bromophenyl]-3-phenylpropanoate 
• 250214-37-0 (+/-)-toluene-4-sulphonic acid 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl ester 
• 1135493-18-3 C₂₀H₁₈O₈*C₂₈H₃₄BrNO 
• 1429299-06-8 R-(-)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid (1S,2R)-ephedrine salt 
• 1185739-54-1 (+/-)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid 
• 100-44-7 benzyl chloride 
• 1429299-08-0 R-(-)-N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionamide 
• 1429299-07-9 (3R)-3-[2-(benzyloxy)-5-bromophenyl]-3-phenylpropanoyl chloride 
• 865889-33-4 R-(-)3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid 

Downstream Products

• 250214-39-2 (-)-N,N-diisopropyl-3-(2-benzyloxy-5-hydroxymethylphenyl)-3-phenylpropylamine 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF FESOTERODINE OR ITS SALTS

The present invention relates to a process for the preparation of fesoterodine or its salts.

PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST

The present invention relates to novel and improved processes for the preparation of (r)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenylisobutyrate represented by the following structural formula-1 and its pharmaceutically acceptable salts thereof.

IMPROVED PROCESS FOR DIPHENYLPROPYLAMINE DERIVATIVES

The present invention relates to an improved process for the preparation of biologically active diphenylpropylamine derivatives. The present invention specifically relates to an improved fesoterodine of formula (I) and its pharmaceutically acceptable salts.

SOLID STATE FORMS OF FESOTERODINE INTERMEDIATES

Provided herein are novel solid state forms of fesoterodine intermediates, (R)-4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzoic acid and (R)-[4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-methanol, and processes for their preparation thereof. The solid state intermediates are useful for preparing fesoterodine or a pharmaceutically acceptable salt thereof in high purity.